Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Q2 Revenues Up Slightly, Losses Widen

NEW YORK, Aug. 3, (GenomeWeb News) - Bruker Biosciences today reported increased revenues for the second quarter, amid widened net losses.

 

The Billerica, Mass., company reported $64.1 million in revenues for the quarter ended June 30, compared to $60.9 million for the comparable period last year. Losses totaled $4.7 million, or .05 per share, up from $1.6 million, or .02 per share, for the year-ago quarter.

 

The company warned of lower-than expected revenues for the quarter July 15.

 

R& D expenses increased to $10.9 million, compared to $9.7 million for the second quarter of 2003.

 

As of June 30, the company had $79.2 millon in cash and short-term investments, compared to $76.8 million as of December 31, 2003.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.